Prescribing Advice for GPs

An NHS Prescribing Advisers' Blog

SMC reject rimonobant

The Scottish Medicines Consortium (SMC) has rejected rimonobant (Acomplia®) for use on the NHS in Scotland.

The recommendation states that the economic case has not been demonstrated although it also indicates that a resubmission is likely.

Rimonobant has already been identified as having a lower place in therapy by the Midlands Therapeutic Review and Advisory Committee and it was previously recommended as a fourth line option when it was launched.

Action: Until an economic case is demonstrated it would be sensible to restrict prescribing of rimonobant to patients who have already started treatment and are achieving weight loss.

Share 'SMC reject rimonobant' on Email Share 'SMC reject rimonobant' on Delicious Share 'SMC reject rimonobant' on Digg Share 'SMC reject rimonobant' on Facebook Share 'SMC reject rimonobant' on Google+ Share 'SMC reject rimonobant' on reddit Share 'SMC reject rimonobant' on StumbleUpon Share 'SMC reject rimonobant' on Twitter

atomic-wealth

No Comments to “SMC reject rimonobant”

Leave a Comment

(required)

(required)


Prescribing Advice for GPs is powered by WordPress.
Subscribe for Free to our RSS or Atom Feeds for New Entries.
Akismet has protected Prescribing Advice for GPs from 789,518 spam comments.

atomic-wealth
fond-illness
summer